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Abstract (249 words out of 250 words max) 36 
 Among emerging non-albicans Candida species, C. parapsilosis is of particular 37 
concern as a cause of nosocomial bloodstream infections in neonatal and intensive care 38 
unit patients.  While fluconazole and echinocandins are considered effective treatment 39 
of such infections, recent reports of fluconazole and echinocandin resistance in C. 40 
parapsilosis indicate a growing problem.  The present study describes a novel 41 
mechanism of antifungal resistance in this organism affecting the susceptibility of azole 42 
and echinocandin antifungals in a clinical isolate obtained from a patient with prosthetic 43 
valve endocarditis.  Transcriptome analysis indicated differential expression of several 44 
genes in the resistant isolate including upregulation of ergosterol biosynthesis pathway 45 
genes ERG2, ERG5, ERG6, ERG11, ERG24, ERG25, and UPC2.  Whole-genome 46 
sequencing revealed the resistant isolate possessed an ERG3 mutation resulting in a 47 
G111R amino acid substitution.  Sterol profiles indicated a reduction in sterol 48 
desaturase activity as a result of this mutation. Replacement of both mutant alleles in 49 
the resistant isolate with the susceptible isolate’s allele restored wild-type susceptibility 50 
to all azoles and echinocandins tested. Disruption of ERG3 in the susceptible and 51 
resistant isolates resulted in a loss of sterol desaturase activity, high-level azole 52 
resistance, and an echinocandin-intermediate to -resistant phenotype.   While disruption 53 
of ERG3 in C. albicans resulted in azole resistance, echinocandin MICs, while elevated, 54 
remained within the susceptible range.  This work demonstrates that the G111R 55 
substitution in Erg3 is wholly responsible for the altered azole and echinocandin 56 
susceptibilities observed in this C. parapsilosis isolate and is the first report of an ERG3 57 
mutation influencing susceptibility to the echinocandins. 58 
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Introduction 59 
Candida species are among the most common causes of bloodstream infections 60 
in the United States and are associated with high morbidity and mortality.  While C. 61 
albicans is the most commonly isolated causative agent of candidemia, infections due to 62 
other non-albicans species of Candida have been increasing in recent decades (1-3).  63 
Of these, Candida parapsilosis is of particular concern as a human fungal pathogen.  It 64 
exhibits a wide growth capacity on surfaces, such as prosthetic materials and 65 
intravascular devices and grows well within parenteral nutrition.  It persists in hospital 66 
environments and may be transmitted nosocomially via hand carriage.  Low weight 67 
neonates and intensive care patients are among the highest at risk for infections with C. 68 
parapsilosis (4).  Relative to what is known in C. albicans, there is little information 69 
regarding the mechanisms by which antifungal drug resistance develops in C. 70 
parapsilosis.  Uniquely among Candida species, C. parapsilosis demonstrates intrinsic 71 
reduced in vitro susceptibility to the echinocandins, presumably as a result of a 72 
naturally-occurring polymorphism in FKS1 (5).  While uncommon, clinical resistance to 73 
this class of antifungals has emerged in C. parapsilosis (6, 7).  Azole resistance, on the 74 
other hand, is more common in C. parapsilosis, with rates of fluconazole resistance 75 
being approximately five times that of C. albicans (8).  Recent reports indicate that 76 
overexpression of the drug efflux pump Mdr1 as well as an increase in, or mutation of, 77 
the target of the azoles, Erg11, contributes to azole resistance in this species (9-12). 78 
In this study, we investigated the mechanisms underlying antifungal drug 79 
resistance in a clinical isolate of C. parapsilosis by comparing it to a genetically-80 
matched, antifungal-susceptible isolate from the same patient.  Through whole 81 
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transcriptome and genome sequence analysis and allelic replacement, we demonstrate 82 
that a mutation in ERG3 leads to resistance to the azole antifungals via alternate sterol 83 
production.  Additionally, we discover that this mutation in ERG3, as well as its 84 
disruption, also causes increased resistance to the echinocandins.  This is the first 85 
report of an ERG3-related resistance mechanism in C. parapsilosis and is the first 86 
evidence in any Candida species that such mutations also influence susceptibility to the 87 
echinocandins. 88 
 89 
Results 90 
Clinical Isolates and Susceptibility Testing 91 
The C. parapsilosis isolates used in this study were collected over the course of multiple 92 
hospitalizations from a patient with aortic valve endocarditis, as outlined elsewhere (13). 93 
These isolates were kindly provided by Dr. Jose Vazquez. The originally reported 94 
antifungal susceptibilities (using the previous CLSI M27-A2 recommended 95 
methodologies) for both the susceptible isolate collected at initial admission (Isolate 1) 96 
as well as for the subsequently collected resistant isolate (Isolate 2) for several azoles, 97 
echinocandins, and amphotericin B are shown in Tables 3A and 3B. MIC (minimum 98 
inhibitory concentration) values for fluconazole, itraconazole, voriconazole, 99 
posaconazole, caspofungin, anidulafungin, micafungin, and amphotericin B were 100 
independently determined for this study by the Fungus Testing Laboratory at the 101 
University of Texas Health Sciences Center at San Antonio (Tables 3A and 3B).  Isolate 102 
1 was susceptible to all azoles tested when read at both 24 and 48 hours, and likewise 103 
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to amphotericin B and all echinocandins tested (determined at 24 hours).  Interestingly, 104 
when determined at 24 hours, Isolate 2 appeared susceptible to all azoles tested, 105 
whereas when determined at 48 hours, was resistant to all azoles tested.  These results 106 
were consistent upon repeat testing.   Isolate 2 also exhibited an increase in MIC for the 107 
echinocandins, reaching the intermediate range for micafungin and anidulafungin.  No 108 
change in susceptibility to amphotericin B was observed.  In separate experiments, 24 109 
and 48 hours growth curves were plotted for fluconazole MIC cultures (Figure 1).  At 110 
both timepoints Isolate 2 phenocopied the erg3Δ/erg3Δ mutants. 111 
 112 
Transcriptional Profiling Reveals Increased Expression of Ergosterol Biosynthesis 113 
Genes 114 
Global changes in gene expression between Isolates 1 and 2 were determined 115 
by RNA sequencing. A total of 378 genes (Table S1) were observed to be reproducibly 116 
upregulated by a minimum of 1.5-fold in the resistant isolate as compared to the 117 
susceptible isolate. Of note, only three of these genes (UPC2, ATC1, and 118 
CPAR2_400860) have been characterized in C. parapsilosis at this time. Gene 119 
Ontology term analysis performed using the Candida Genome Database 120 
(www.candidagenome.org) revealed genes of the sterol metabolic process to be the 121 
most significantly enriched among all upregulated genes (p=2.96e-5). Of these 14 122 
genes, as shown in Table 4, the sterol regulatory transcription factor UPC2 and the C. 123 
parapsilosis orthologs of identified CaUpc2 target genes (ERG1, ERG2, ERG5, ERG6, 124 
ERG11, ERG24, and ERG25) are included (14). Differential expression of key 125 
ergosterol biosynthesis genes, as well as the lack of a change in expression of the 126 
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multidrug transporter genes CDR1, CDR2, and MDR1, were confirmed with qRT-PCR 127 
(data not shown). An additional 32 genes were observed to be upregulated in the 128 
resistant isolate, but the extent of which could not be reliably quantified due to extremely 129 
low transcript counts in the susceptible isolate (Table S2). Genes which are 130 
reproducibly downregulated in the resistant isolate as compared to the susceptible 131 
isolate are listed in Table S3.  132 
 133 
Next Generation Sequencing Identifies a SNP in ERG3 in the Resistant Isolate   134 
 To further characterize this matched isolate pair, whole genome sequencing was 135 
used to identify single nucleotide polymorphisms occurring in Isolate 2 as compared to 136 
Isolate 1 (Figure 2).  There was a total of 462 SNPs detected, involving 305 individual 137 
genes.  Many of the genes containing SNPs are involved in cell adhesion, biofilm 138 
formation, and cytoskeletal rearrangement.  A homozygous nonsynonymous mutation 139 
was detected in ERG3, substituting a glycine to an arginine at position 111.  This 140 
polymorphism was confirmed by Sanger-based sequencing (data not shown).  141 
 142 
Analysis of Copy Number Variation and Loss of Heterozygosity 143 
  The Yeast Mapping Analysis Pipeline (Ymap; lovelace.cs.umn.edu/Ymap) was 144 
used to identify chromosomal copy number variation (CNV) and loss of heterozygosity 145 
(LOH) between Isolate 1 and Isolate 2 (15). CNV and SNP analysis of Isolate 1 146 
revealed no segmental or chromosomal CNV, and scattered regions of increased 147 
heterozygosity across each chromosome (Figure 3A). Using the Isolate 1 analysis as a 148 
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parental reference isolate, the WGS data for Isolate 2 was then assessed. Unlike its 149 
parent isolate, Isolate 2 exhibited segmental tetraploidy in a single chromosome 150 
(Contig005809). In this region, containing 113 genes (Table S4), complete duplication 151 
across approximately 233,000 bases was observed (Figure 3B).  Additionally, LOH 152 
analysis revealed that while relatively little allelic variation was present in Isolate 1, 153 
much of this variation has been lost in Isolate 2 (Figure S1). 154 
 155 
Loss of Erg3 Activity Confers Increased Resistance to Echinocandins in C. parapsilosis 156 
and to a Lesser Extent C. albicans 157 
We first deleted both alleles of ERG3 in both the susceptible (Isolate 1) and 158 
resistant (Isolate 2) isolates. As expected, loss of ERG3 resulted in resistance to all 159 
azoles tested (Table 3A).  Surprisingly, deletion of ERG3 also resulted in MICs that fell 160 
within the intermediate to resistant range for the echinocandins (Table 3B).  In order to 161 
determine if this also occurs in the related species C. albicans, we tested the 162 
echinocandin susceptibilities of two independent ERG3 deletion mutants constructed in 163 
two different backgrounds.  In both cases deletion of ERG3 resulted in negligible 164 
increases in echinocandin MICs (Table 3B).   165 
 166 
The G111R Substitution in Erg3 Confers Reduced Susceptibility to Azoles and 167 
Echinocandins  168 
In order to directly assess the role of the G111R amino acid substitution in Erg3 169 
in the reduced susceptibility to azoles and echinocandins, we introduced the wild-type 170 
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ERG3 alleles from the susceptible isolate (Isolate 1) into its resistant counterpart 171 
(Isolate 2), creating a homozygous mutant, and performed susceptibility testing against 172 
azoles and echinocandins. Introduction of the wild-type ERG3 alleles to Isolate 2 173 
restored susceptibility to all azoles tested (Tables 3A and 3B). Surprisingly, 174 
susceptibility to the echinocandins was also restored to the levels observed in Isolate 1.  175 
 176 
The G111R Substitution in Erg3 Leads to Alterations in Sterol Biosynthesis 177 
As the mutation in ERG3 is not a nonsense mutation, we questioned if, 178 
alternatively, the activity of Erg3 is reduced by this mutation, leading instead to a less 179 
functional protein.  Perturbations in this protein would be evident with increases in 180 
accumulated ergosta-7,22-dienol, episterol, and ergosta 7-enol.  Sterol profiles were 181 
obtained using GC/MS and are shown in Table 5.  Isolate 1 exhibits a reasonably 182 
normal sterol profile in which ergosterol comprised the highest percentage.  On the 183 
other hand, Isolate 2 exhibits profiles in which ergosta-7-enol and ergosta-7,22-dienol 184 
represented the largest portion of the total cell fraction. This is consistent with a 185 
reduction in sterol desaturase activity. Upon replacement of the mutant ERG3 alleles in 186 
Isolate 2 with the wild-type allele from Isolate 1, normal sterol profiles were restored. 187 
Deletion of ERG3 in both Isolate 1 (susceptible isolate) and Isolate 2 (resistant isolate) 188 
resulted in profiles consistent with complete loss of Erg3 activity. 189 
 190 
Discussion 191 
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Most of what is known about the genetic basis of antifungal resistance has been 192 
determined from C. albicans.  Mechanisms of azole resistance in this species include 193 
overexpression of the gene encoding the target enzyme, Erg11, and nonsynonymous 194 
mutations in both ERG11 and ERG3.  Additionally, upregulation of drug efflux pumps 195 
represents an additional mechanism of azole resistance; ABC transporters Cdr1 and 196 
Cdr2 confer resistance to multiple azoles, while the MFS transporter Mdr1 confers 197 
resistance to fluconazole, ketoconazole, and voriconazole (16).  Echinocandins, on the 198 
other hand, function by inhibiting β-D-glucan synthase activity, encoded by FKS1 in C. 199 
albicans and FKS1 and FKS2 in S. cerevisiae (17). Although mutations within FKS 200 
genes have been linked to echinocandin resistance in several species of Candida (18), 201 
there are also additional mechanisms by which this resistance may occur.  These 202 
include the activation of signaling pathways which regulate stress response and PKC 203 
cell wall integrity, as well as synthesis of ancillary cell wall components such as chitin 204 
and mannan (19).  205 
 In the present study, RNA sequencing revealed the genes that are differentially 206 
expressed between these two genetically-related clinical isolates.  We did not observe 207 
overexpression of any gene encoding a characterized multidrug transporter suggesting 208 
that azole resistance was unlikely due to reduced intracellular accumulation of drug.  209 
Furthermore, the observed 1.6 to 2.6- fold increased expression of ERG11 in the 210 
resistant isolate, as compared to the susceptible isolate, would alone not be expected to 211 
produce high-level pan-azole resistance particularly in the absence of an accompanying 212 
ERG11 mutation.  Lastly, we did not observe any change in gene expression that would 213 
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indicate a root cause for the observed reduction in echinocandin susceptibility, such as 214 
an increase in glucan synthase or chitin synthase expression. 215 
 Notably among the upregulated genes are several involved in the ergosterol 216 
biosynthesis pathway.  This biosynthetic pathway results in the production of an 217 
essential fungal membrane component, ergosterol, and inhibition of the azole target 218 
sterol demethylase leads to production of toxic sterol intermediates (20).  The azoles 219 
exploit this and function specifically by inhibiting the enzyme 14α- lanosterol 220 
demethylase, encoded by ERG11, leaving the cell unable to produce ergosterol (21).  221 
The genes which were observed to be upregulated within the resistant isolate, ERG1, 222 
ERG2, ERG5, ERG6, ERG11, ERG24, ERG25, ERG27, and DAP1, encode various 223 
proteins involved in sterol processing within this pathway and are located both upstream 224 
and downstream of the azole target, Erg11. Additionally, the gene encoding the sterol 225 
regulatory transcription factor Upc2 was upregulated. These observations are consistent 226 
with loss of sterol desaturase activity leading to decreased membrane ergosterol and 227 
activation of Upc2.  In this way, an upregulation of these critical genes represents a 228 
response to facilitate increased conversion of lanosterol to ergosterol in the event that 229 
production had declined or been disrupted.  This is further supported by the results of 230 
the whole genome sequencing of the isolate pair.  Among a relatively small number of 231 
SNPs detected in the resistant isolate which do not occur in the susceptible isolate, a 232 
nonsynonymous mutation was identified in ERG3.  This gene is located downstream in 233 
the ergosterol biosynthesis pathway relative to the genes found to be upregulated by 234 
RNA sequencing.  The amino acid substitution, at position 111 of the predicted protein, 235 
changes a glycine to an arginine. 236 
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Mutation within ERG3 has been documented in clinical isolates as well as 237 
passage-derived isolates of C. albicans and linked to both amphotericin B resistance 238 
and high-level azole resistance (22, 23). When azoles inhibit the function of 14α-239 
demethylase and therefore the production of ergosterol, ERG3 encodes an enzyme 240 
which converts the nontoxic 14α-methylated sterol intermediates into the toxic sterol 241 
14α-methyl-ergosta-8,24 (28)-dien-3,6-diol.  A reduction in or loss of this enzyme results 242 
instead in the accumulation of nontoxic ergosta-7,22-dienol.  This leads to high levels of 243 
resistance to the azole drug class.  244 
The loss of ergosterol in the yeast cell membrane, the target of amphotericin B, 245 
has been reported to result in resistance to this antifungal (24-26).  However, using 246 
standard CLSI methods, we did not observe a reproducible increase in amphotericin B 247 
MIC at 24 or 48 hours for the C. parapsilosis or C. albicans mutants deleted for ERG3 248 
or for the C. parapsilosis mutant expressing the G111R mutation.  The majority of ERG3 249 
mutations reported in the literature result in premature stop codons; however, there 250 
have been cases in which the strains instead exhibit nonsynonymous mutations, as 251 
observed in this isolate pair (22, 27-29).   252 
The finding that the G111R amino acid substitution also explained the reduced 253 
susceptibility to the echinicandins observed in this isolate was unexpected as, until now, 254 
alterations in sterol desaturase activity have not been associated with this phenotype.  It 255 
is important to note that deletion of ERG3 had a similar effect on echinocandin 256 
susceptibility in C. parapsilosis, but this was not the case when ERG3 was deleted in C. 257 
albicans.  It is possible that a mutation in ERG3 that impairs sterol desaturase activity, 258 
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combined with the naturally-occurring polymorphism in FKS1 in C. parapsilosis, 259 
uniquely impacts echinocandin susceptibility in this Candida species.  260 
Our finding of an ERG3 mutation as a cause of azole resistance in this clinical 261 
isolate is supported by the recent work of Branco et al (30).  In this study, a C. 262 
parapsilosis strain that was evolved to become resistant to posaconazole in the 263 
laboratory was found to have a similar (R135I) mutation in ERG3 resulting in resistance 264 
to fluconazole, voriconazole, and posaconazole.  Echinocandin susceptibilities however 265 
were not reported.   266 
This matched isolate pair provided an opportunity to evaluate factors contributing 267 
to a unique case of antifungal resistance. We reasoned that the mechanism(s) 268 
underlying this resistance would be detectable among differences in gene expression 269 
and/or whole genome sequence analysis. Here we have demonstrated that a mutation 270 
in ERG3, which encodes a key enzyme for the production of the membrane sterol 271 
ergosterol, increases resistance to not only the azoles but also to the echinocandins in a 272 
clinical isolate.  This is the first report of a mutation in ERG3 influencing the 273 
susceptibility to the echinocandins and of a single mechanism that affects susceptibility 274 
to these two important classes of antifungals.   275 
 276 
Materials and Methods 277 
Strains and media.  All C. parapsilosis isolates used in this study are listed in 278 
Table 1.   Isolates were kept as frozen stock in 40% glycerol at −80°C and subcultured 279 
on YPD (1% yeast extract, 2% peptone, and 1% dextrose) agar plates at 30°C. YPD 280 
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liquid medium was used for routine growth of strains, while YPM (1% yeast extract, 2% 281 
peptone, 1% maltose) liquid medium was used for induction of the MAL2 promoter in 282 
constructed strains.  Nourseothricin (200 μg/ml) was added to YPD agar plates for 283 
selection of isolates containing the SAT1-flipper cassette (31). One Shot Escherichia 284 
coli TOP10 chemically competent cells (Invitrogen) were used for plasmid construction. 285 
These strains were grown in Luria-Bertani (LB) broth or on LB agar plates 286 
supplemented with 100 μg/ml ampicillin (Sigma) or 50 μg/ml kanamycin (Fisher 287 
Bioreagents), when needed.  288 
Drug Susceptibility Testing.  Susceptibility testing was performed by broth 289 
microdilution according to the methods in the CLSI M27-A3 reference standard (32). 290 
Testing was performed in at least duplicate for each isolate and each antifungal agent.  291 
The starting inoculum was between 0.5 – 2.5x103 cells /ml, and all testing was 292 
performed in RPMI 1640 with 0.2% glucose, buffered with 0.165M MOPS and adjusted 293 
to pH 7.0.  Plates were incubated at 35°C, and MICs were read visually for the 294 
echinocandins and azoles at the lowest concentration that resulted in 50% growth 295 
inhibition compared to the drug free growth control at both 24 and 48 hours.  For 296 
amphotericin B, the MIC was read as complete inhibition of growth at each of these time 297 
points. 298 
The susceptibility results for fluconazole were also repeated and verified by broth 299 
microdilution using a microplate spectrophotometer with optical density readings as the 300 
endpoint.  Each strain was tested at least in triplicate. Cultures were diluted to 2.5x103 301 
cells/ml in sterile RPMI 1640 (Sigma, St. Louis, MO) with 2% glucose, buffered with 302 
0.165 M MOPS and adjusted to pH 7.0. Plates were incubated at 35°C for 24 and 48 h 303 
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with shaking. Optical density at 600 nm was read with a Biotek Synergy 2 microplate 304 
reader (Fisher Scientific, Waltham, MA); background due to medium was subtracted 305 
from all readings. The relative growth was calculated as the percentage of cell growth in 306 
drug containing medium relative to the cell growth in the absence of drug; the results 307 
were plotted as percent inhibition versus fluconazole concentration. 308 
Construction of Plasmids.  All primers used are listed in Table 2.  An ERG3 309 
deletion construct for C. parapsilosis was generated by amplifying an ApaI-XhoI-310 
containing fragment consisting of flanking regions upstream -280 to +51 relative to the 311 
start codon of C. parapsilosis ERG3 using primers ERG3-A and ERG3-B, as well as a 312 
NotI-SacII-containing fragment of downstream flanking regions +1047 to +1868 using 313 
primers ERG3-C and ERG3-D.  These upstream and downstream fragments of ERG3 314 
were cloned upstream and downstream, respectively, of the SAT1-flipper cassette in 315 
plasmid pSFS2 to result in plasmid p77ERG3. Additionally, the coding region of ERG3 316 
was amplified from either the Isolate 1 or Isolate 2 with primers ERG3-A and ERG3-E.  317 
Each of these ApaI-XhoI-containing fragments replaced the upstream sequence in 318 
cassette p77ERG3 to introduce the entire gene, creating plasmids p77ERG3comp and 319 
p76ERG3. 320 
Similarly, an ERG3 deletion construct for C. albicans was generated by 321 
amplifying an ApaI-XhoI-containing fragment consisting of flanking regions upstream -322 
350 to +39 relative to the start codon of C. albicans ERG3 using primers CaERG3A-F 323 
and CaERG3B-R, as well as a NotI-SacII-containing fragment consisting of flanking 324 
regions +997 to +1677 downstream of the start codon using primers CaERG3C-F and 325 
CaERG3D-R.  These upstream and downstream fragments were cloned upstream and 326 
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downstream, respectively, of the SAT1-flipper cassette in plasmid pSFS2, resulting in 327 
pCaERG3M1. 328 
Candida parapsilosis Transformation.  C. parapsilosis strains were transformed 329 
by electroporation as described previously but with some modifications (31). Cells were 330 
grown for 6 hours in 2 mL YPD liquid medium and then 4 μL of this cell suspension was 331 
passed to 50 mL of fresh YPD liquid medium and grown overnight at 30°C in a shaking 332 
incubator. When the culture’s optical density at 600 nm reached 2.0, cells were 333 
collected by centrifugation, resuspended in 1 mL 10x TE buffer, 1 mL lithium acetate, 334 
and 8 mL of deionized water, and then reincubated at 30°C for 1 hour.  Freshly 335 
prepared 1M dithiothreitol was added to the cell suspension, and cells were incubated 336 
for an additional 30 minutes. Cells were then washed twice with ice-cold water and then 337 
once with ice-cold 1 mM sorbitol. Finally, the cells were resuspended in 100 μL of fresh 338 
ice-cold 1 mM sorbitol.  The gel-purified ApaI-SacI fragment from the appropriate 339 
plasmid was mixed with 40 μL of competent cells and transferred into a chilled 2-mm 340 
electroporation cuvette.  The reaction was carried out at 1.5 kV, using a Cellject Pro 341 
Electroporator (Thermo).  Immediately following, 1 mL of YPD containing 1 M sorbitol 342 
was added and the mixture was transferred to a 1.5 mL centrifuge tube.  Cells were 343 
allowed to recover at 30°C for 6 hours.  Finally, 100 μL was removed and plated to YPD 344 
agar plates containing 200 μg/mL nourseothricin and 1 M sorbitol. Transformants were 345 
selected after at least 48-hours growth at 30°C. 346 
RNA Isolation and Sequencing. RNA was isolated using the hot phenol method 347 
of RNA isolation described previously (33).  RNA concentrations were determined using 348 
a Nanodrop spectrophotometer (Nanodrop Products), and RNA integrity was verified 349 
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using a Bioanalyzer 2100 (Agilent Technologies).  Barcoded libraries were prepared 350 
using the Lexogen mRNA Sense kit for Ion Torrent according to manufacturer’s 351 
standard protocol. Libraries were sequenced on the Ion Torrent Proton sequencer. 352 
Individual sample fragments were concatenated to form the whole sample fastq file. 353 
Files were then run through FASTQC to check data quality. Any reads with a phread 354 
score <20 were trimmed. Reads were then aligned to the C. parapsilosis CDC317 355 
reference transcriptome using RNA-Star long method. After alignment, transcriptome 356 
alignment counts were gathered. The read counts for each sample were normalized 357 
using transcripts per kilobase million (TPM) method.  These data have been deposited 358 
in the Gene Expression Omnibus repository under the accession number GSE98986. 359 
Southern Hybridization. Genomic DNA (gDNA) for use with Southern blotting was 360 
prepared as described previously (34), digested with appropriate restriction 361 
endonucleases, separated on a 1 % agarose gel, stained with ethidium bromide, and 362 
transferred by vacuum blotting to a nylon membrane.  After UV crosslinking, 363 
membranes were probed and detected using the Amersham ECL Direct nucleic acid 364 
labeling and detection system according to the manufacturer’s instructions. 365 
Whole Genome Sequencing.  Genomic DNA for library preparation was isolated 366 
using Qiagen Genomic-tip 100/G kit (Qiagen) following the manufacturer’s Genomic 367 
DNA Preparation instructions. Paired-end DNA sequence libraries for Isolate 1 and for 368 
Isolate 2 were prepared and sequenced using the Ion Proton Torrent sequencer and 369 
aligned to the C. parapsilosis CDC317 reference genome sequence. The GATK Best 370 
Practices work flow was used, incorporating the following tools: bwa (193) v0.5.9 (aln 371 
and sample), Picard tools (http://picard.sourceforge.net) v1.107 (SortSam and 372 
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MarkDuplicates), samtools (194) v0.1.19 and GATK (195) v2.8.  373 
(RealignerTargetCreateor, IndelRealigner, BaseRecalibrator, PrintReads, 374 
ReduceReads, HaplotypeCaller).  A population variants file for C. parapsilosis was 375 
downloaded from the Broad Institute website (https://www.broadinstitute.org/fungal-376 
genome-initiative) and used as the –knownSites file in the GATK BaseRecalibrator step.  377 
The snpEff (196) v3.5 genetic variant annotation tool was used to annotate SNP and 378 
indel variants using the c_parapsilosis_CDC317 snpEff database.  The GATK 379 
CombineVariants and SelectVariants tools were used to select SNPs found in Isolate 2 380 
but not in Isolate 1 and SNPs that are heterozygous in Isolate 1 and homozygous in 381 
Isolate 2.  The JBrowse Genome Browser (197) v1.11.6 was used to visualize 382 
sequence alignments at genomic positions in order to validate variant calls (35). 383 
Following installation of the C. parapsilosis CDC317 reference genome using the 384 
current chromosomal features file available at the Candida Genome Database 385 
(www.candidagenome.org), the whole genome sequencing (WGS) data for the parental 386 
Isolate 1 was uploaded and aligned to the reference chromosome map using Ymap 387 
(lovelace.cs.umn.edu/Ymap). WGS data for Isolate 2 was then installed utilizing Isolate 388 
1 as the parental strain to allow for loss of heterozygosity (LOH) analysis (15).  The 389 
NCBI accession number for these data is PRJNA361149. 390 
Sequence Analysis of ERG3. The coding sequence of ERG3 in C. parapsilosis 391 
was amplified by PCR from C. parapsilosis genomic DNA using the primers listed in 392 
Table 2, cloned into pCR-BLUNTII-TOPO using a Zero Blunt TOPO PCR cloning kit, 393 
and transferred into Escherichia coli TOP10 cells with selection on LB agar plates 394 
containing 50 µg/ml kanamycin. Plasmid DNA was purified (QIAquick PCR Purification 395 
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Kit,  Qiagen) and sequenced on an ABI model 3130XL genetic analyzer using 396 
sequencing primers, resulting in a full-length sequence from both strands of ERG3.  The 397 
sequencing was performed using a total of six sets of clones derived from three 398 
independent PCR reactions.  The coding sequence of ERG3 in Isolate 2 described in 399 
this study has been deposited in GenBank under accession number KT277771. 400 
Sterol Analysis. Non-saponifiable lipids were extracted using alcoholic KOH.  401 
Samples were dried in a vacuum centrifuge (Heto) and were derivatized by the addition 402 
of 100 µl 90% BSTFA/ 10% TMS (Sigma), 200 µl anhydrous pyridine (Sigma) and 403 
heating for 2 hours at 80oC.  TMS-derivitized sterols were analyzed and identified using 404 
GC/MS (Thermo 1300 GC coupled to a Thermo ISQ mass spectrometer, Thermo 405 
Scientific) with reference to retention times and fragmentation spectra for known 406 
standards.  GC/MS data files were analyzed using Xcalibur software (Thermo Scientific) 407 
to determine sterol profiles for all isolates and for integrated peak areas (20). 408 
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Table 1. C. parapsilosis strains and isolates used in this study 530 
Strain/Isolate (Name) 
Strain 
Background Relevant Genotype/Characteristics Reference
C. parapsilosis 
     35177 (Isolate 1) N/A Antifungal drug susceptible 13 
     35176 (Isolate 2) N/A Antifungal drug resistant 13 
     E77U7G3 (Isolate 1- erg3Δ/Δ) Isolate 1 erg3Δ::FRT/erg3Δ::FRT This study 
     76B2E19 (Isolate 2- erg3Δ/Δ) Isolate 2 erg3Δ::FRT/erg3Δ::FRT This study 
     76C1B4 (Isolate 2- ERG3WT/WT) 76B2E19 erg3Δ:: ERG3WT -FRT/ erg3Δ::ERG3WT-FRT This study 
C. albicans 
     SC5314 N/A wild-type - 
     ScERG3M4C (SC5314- erg3Δ/Δ) SC5314 erg3Δ::FRT/ erg3Δ::FRT This study 
     GP1 (BR1- ERG3WT/WT ) BWP17 his1Δ/Δ::HIS1 arg4Δ/Δ::ARG4 ura3Δ/Δ::IRO1-URA3 This study 
     E3AL1 (BR2- erg3Δ/Δ) BWP17 erg3Δ::ARG4/erg3Δ:HIS1 ura3Δ/Δ::IRO1-URA3 This study 
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Table 2. Primers used in this study 531 
Primer Sequencea 
C. parapsilosis Gene Disruption/Complementation 
ERG3-A 5’-GACAAACAAAATAAGGGCCCAAAATTAAAGG-3’ 
ERG3-B 5’- AGCATATAGTCTCTCGAGTAGGTAATAAT-3’ 
ERG3-C 5’-GATAGCCGCGGAAGATCATACAGAAGAC-3’ 
ERG3-D 5’-AAAATAGAGCTCCTGGGTGGGAATTAT -3’ 
ERG3-E 5’-AAAATACAGTTACTCGAGGGGAATTAT-3’ 
C. parapsilosis ERG3 Sequencing 
ERG3-A 5’-CCCACGTTTATTTCACTAGATCC-3’ 
ERG3-B 5’-GGTTGCCTTGACCAACCC-3’ 
ERG3-C 5’-GGGAATGGGCAATAGGGACAC-3’ 
ERG3-D 5’-GGTTGCCTTGACCAACCC-3’ 
C. albicans Gene Disruption 
CaERG3A-F 5’- ATCTGATTTATATATGGGCCCAAGTGTTTG-3’ 
CaERG3B-R 5’-AAAAGATAATAGTCTCGAGTTTCTAGTACG-3’ 
CaERG3C-F 5’-ATAGCCGCGGTAACTCTTACAGAAGACC-3’ 
CaERG3D-R 5’-TGTGATGTGAGCTCGTTAGTATTATTTTCA-3’ 
a- Underlined sequences indicate introduced restriction sites.  532 
  533 
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Table 3A. Azole antifungal susceptibilities for C. albicans and C. parapsilosis isolates a  534 
 Fluconazole Voriconazole Itraconazole Posaconazole
Isolate 24h 48h 24h 48h 24h 48h 24h 48h 
C. parapsilosis                 
     Isolate 1 b   1    0.03          
     Isolate 2 b   >64    >16          
     Isolate 1 0.25 0.25 0.25 0.5 ≤0.03 ≤0.03 0.06 ≤0.03 ≤0.03 ≤0.03 ≤0.03 0.06 ≤0.03 ≤0.03 ≤0.03 ≤0.03
     Isolate 2 ≤0.125 ≤0.125 >64 >64 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16
     Isolate 1- Δerg3 ≤0.125 ≤0.125 >64 >64 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16
     Isolate 2- Δerg3 ≤0.125 ≤0.125 >64 >64 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16 ≤0.03 ≤0.03 >16 >16
     Isolate 2-ERG3WT/WT 0.25 0.25 ≤0.125 0.5 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03 0.06 0.125 ≤0.03 ≤0.03 0.06 ≤0.03
C. albicans                 
     SC5314 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.03 ≤0.03 ≤0.03 ≤0.03 0.06 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03
     SC5314- Δerg3 >64 >64 >64 >64 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16
     BWP17 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.03 ≤0.03 0.06 ≤0.03 ≤0.03 ≤0.03 ≤0.03 ≤0.03 0.125 ≤0.03 0.06 ≤0.03
     BWP17- Δerg3 >64 >64 >64 >64 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16
a- All values are in µg/ml; values in bold are resistant. 535 
b- MIC values as reported previously determined using the previous CLSI M27-A2 recommended methodologies (13). 536 
  537 
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Table 3B. Echinocandin and amphotericin B susceptibilities for C. albicans and C. 538 
parapsilosis isolates a 539 
a- All values are in µg/ml; values in bold are non-susceptible according to CLSI clinical 540 
breakpoints. 541 
b- MIC values as reported previously determined using the previous CLSI M27-A2 542 
recommended methodologies (13). 543 
  544 
 Anidulafungin Caspofungin Micafungin Amphotericin B
Isolate 24h 48h 24h 48h 24h 48h 24h 
C. parapsilosis            
     Isolate 1 b - - 1 - - 2 - - 8 0.25  
     Isolate 2 b - - 2 - - >16 - - >16 0.5  
     Isolate 1 2 2 - 1 1 - 2 2 - 0.5 0.5 
     Isolate 2 4 4 - 2 1 - 4 4 - 0.5 0.5 
     Isolate 1- Δerg3 4 4 - 2 2 - 8 8 - 0.5 1 
     Isolate 2- Δerg3 4 4 - 2 2 - 4 4 - 0.5 0.5 
     Isolate 2-ERG3WT/WT 2 2 - 1 0.5 - 2 2 - 0.25 0.5 
C. albicans            
     SC5314 ≤0.015 ≤0.015 - 0.25 0.25 - 0.03 0.03 - 0.25 0.5 
     SC5314- Δerg3 0.06 0.06 - 0.25 0.5 - 0.06 0.06 - 0.5 0.5 
     BWP17 ≤0.015 ≤0.015 - 0.25 0.25 - 0.03 0.03 - 0.25 0.5 
     BWP17- Δerg3 0.06 0.06 - 0.25 0.25 - 0.06 0.06 - 0.5 0.5 
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Table 4. Genes involved in sterol metabolic processes overrepresented among the 545 
upregulated genes in Isolate 2 relative to Isolate 1.  546 
Gene ID 
C. parapsilosis 
Gene Name 
S. cerevisiae 
Gene Name 
C. albicans 
Gene Name 
Fold 
Change 
Sample A 
Fold 
Change 
Sample B
CPAR2_601530 - GRE2 - 4.8 5.0 
CPAR2_201490 - - - 7.2 1.7 
CPAR2_405010 - ERG6 ERG6 2.3 3.8 
CPAR2_202280 - DAP1 DAP1 3.3 1.6 
CPAR2_405900 - ERG24 ERG24 2.0 2.7 
CPAR2_103490 - ATF2 - 2.3 2.2 
CPAR2_801560 - ERG27 ERG27 2.2 2.2 
CPAR2_303740 ERG11 ERG11 ERG11 1.6 2.6 
CPAR2_801410 - ERG25 ERG25 1.8 2.2 
CPAR2_105000 - YEH1 - 2.0 2.0 
CPAR2_210480 - ERG1 ERG1 1.7 2.2 
CPAR2_207280 UPC2 UPC2 UPC2 1.8 1.8 
CPAR2_703970 - ERG5 ERG5 1.6 1.6 
CPAR2_109890 - ERG2 ERG2 1.6 1.5 
 547 
Fold change values represents genes upregulated in Isolate 2 as compared to Isolate 1 548 
a minimum of 1.5- fold in samples from independent experiments A and B. Genes 549 
shown in bold have orthologs regulated by CaUPC2 550 
 551 
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 552 
Table 5. Sterol composition for each isolate and each ERG3 mutant (shown as percent 553 
of total sterols) 554 
Sterol Isolate 1 Isolate 2 
Isolate 1  
erg3Δ/ erg3Δ 
Isolate 2 
ERG3WT/ERG3WT 
Ergosta-5,7,24(28)-
tetranol 
4.0 0.5 0.4 0.5 
Unknown m/z 470 -- -- 7.0 -- 
Zymosterol 4.2 7.5 -- 1.9 
Ergosterol 65.4 9.1 -- 51.8 
Ergosta-7,22-dienol 9.3 71.7 76.8 22.3 
Fecosterol (E8, 24(28)) 1.4 0.6 0.9 0.7 
Ergosta-8-enol -- 0.8 1.2 0.6 
Ergosta 5,7 dienol 6.3 0.4 0.3 8.6 
Episterol (E7, 24(28)) 3.2 3.3 4.2 3.2 
Ergosta-7-enol 1.9 4.2 8.4 6.6 
Lanosterol/obtusifoliol 2.8 0.5 0.3 2.7 
4,4,-diemthyl cholesta-
8,24-dienol 
1.7 1.4 0.6 1.1 
 555 
 556 
 557 
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Figure 1.  Fluconazole MIC growth curves.  Isolates 1 and 2 and their related strains 558 
were grown for (A) 24 hours and (B) 48 hours in the presence of the indicated 559 
concentrations of fluconazole. 560 
Figure 2. Schematic representation of RNA and whole genome sequencing data for 561 
Isolate 2 as compared to Isolate 1. Colored circle segments represent contig 562 
boundaries. The outer track represents RNA sequence data, such that the green lines 563 
indicate those genes which are overexpressed in Isolate 2 by at least 1.5-fold and red 564 
lines indicate those genes which are underexpressed at 0.5-fold or less, relative to 565 
Isolate 1.  The inner track represents sequence variants which are found in Isolate 2 but 566 
not in Isolate 1 for the whole genome sequence data. Overexpressed genes of the 567 
ergosterol biosynthetic process are labeled with S. cerevisiae ortholog gene names.  568 
Figure 3. Horizontal tracks represents the C. parapsilosis contig as labeled. The black 569 
line running horizonatally through each contig represents the the predicted local copy 570 
number, with the center set equal to two, and divergences up or down indicating 571 
increased or decreased copy number at that loci, respectively. A region of segmental 572 
tetraploidy is denoted with an asterisk. Gray vertical lines (A) represent local allelic 573 
variation with the darker gray indicating higher concentrations of heterozygosity. Red 574 
vertical lines (B) represent loss of heterozygosity relative to the parent isolate (Isolate 575 
1), with darker red indicating a greater degree of change in heterozygosity.  576 
 577 
 578 
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